SARS-CoV-2 und das antivirale Interferonsystem (SARS2_IFN) [Google Tranlate: SARS-CoV-2 and the antiviral interferon system (SARS2_IFN)]

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:1 publications

Grant number: 01KI20158

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2021
  • Known Financial Commitments (USD)

    $57,052.89
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

    Pending
  • Research Location

    Germany, Europe
  • Lead Research Institution

    Justus-Liebig-Universität Gießen
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Type I interferons (IFN-alpha / beta) and other cytokines represent the first line of defense against viral infections. IFN activates the expression of more than 300 so-called ISGs (IFN-stimulated genes), some of which are able to deliver viruses directly inhibit. Pathogenic viruses often prevent the induction of IFN, block the signaling triggered by IFN or specifically inactivate individual ISGs. They can also trigger the induction of pro-inflammatory cytokines. The quality and strength of IFN and cytokine induction, IFN evasion, and IFS sensitivity, collectively known as the Innate Immunity phenotype, is an important marker of virulence. The aim of our subproject is to establish systems for the detection of the Innate Immunity phenotype of pre-pandemic respiratory viruses in order to be able to carry out a rapid risk assessment. For this purpose, we will measure the activation of cytokines (including IFN) and antiviral ISGs and create an IFN sensitivity profile for each virus examined. In addition, we will generate a library of ISG-expressing cell lines in order to identify specific ISG resistances and sensitivities. The now largely established systems are now to be applied to the new SARS-CoV-2.

Publicationslinked via Europe PMC

Last Updated:38 minutes ago

View all publications at Europe PMC

Functional comparisons of the virus sensor RIG-I from humans, the microbat Myotis daubentonii, and the megabat Rousettus aegyptiacus, and their response to SARS-CoV-2 infection.